Nurix Therapeutics, Inc. $NRIX Stock Holdings Decreased by Deutsche Bank AG

Deutsche Bank AG cut its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 380,148 shares of the company's stock after selling 151,049 shares during the period. Deutsche Bank AG owned 0.50% of Nurix Therapeutics worth $4,516,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in NRIX. GF Fund Management CO. LTD. acquired a new position in Nurix Therapeutics during the fourth quarter worth $28,000. Aquatic Capital Management LLC purchased a new position in Nurix Therapeutics in the fourth quarter valued at $87,000. Exchange Traded Concepts LLC increased its holdings in Nurix Therapeutics by 38.9% in the first quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock valued at $109,000 after buying an additional 2,562 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after purchasing an additional 877 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of Nurix Therapeutics during the fourth quarter worth about $164,000.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. HC Wainwright decreased their target price on shares of Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, July 14th. Oppenheimer reaffirmed an "outperform" rating and issued a $30.00 target price (down from $32.00) on shares of Nurix Therapeutics in a report on Thursday, July 31st. Stephens reissued an "overweight" rating and set a $30.00 price objective on shares of Nurix Therapeutics in a research note on Thursday, July 10th. UBS Group lowered their target price on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, July 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $27.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $28.87.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,402 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the transaction, the chief financial officer owned 35,512 shares in the company, valued at $391,697.36. The trade was a 13.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gwenn Hansen sold 4,308 shares of the business's stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total transaction of $51,739.08. Following the completion of the transaction, the insider owned 69,023 shares in the company, valued at $828,966.23. This represents a 5.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,014 shares of company stock worth $163,014 in the last quarter. 7.40% of the stock is currently owned by company insiders.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX traded up $0.5710 during midday trading on Friday, hitting $10.2210. 128,142 shares of the company's stock traded hands, compared to its average volume of 862,334. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56. The company has a market cap of $781.40 million, a PE ratio of -3.95 and a beta of 2.14. The firm's fifty day moving average price is $11.44 and its two-hundred day moving average price is $12.17.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. The firm had revenue of $44,056 billion for the quarter, compared to analyst estimates of $16.26 million. As a group, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.